Compass Therapeutics (CMPX) Depreciation & Amortization (CF) (2019 - 2026)

Compass Therapeutics has disclosed Depreciation & Amortization (CF) across 8 years of filings, most recently posting $15000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $15000.0, down 89.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $151000.0 (down 73.74% YoY), and the FY2025 annual result was $276000.0, down 53.14% from the prior year.
• Depreciation & Amortization (CF) came in at $15000.0 for Q1 2026 at Compass Therapeutics, down from $17000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $220000.0 in Q2 2022 to a low of $15000.0 in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $154000.0 (2024), against an average of $138882.4.
• Across the five-year window, Depreciation & Amortization (CF) soared 57.26% in 2022 and tumbled 89.29% in 2026, its largest moves.
• Compass Therapeutics' Depreciation & Amortization (CF) stood at $195000.0 in 2022, then dropped by 17.44% to $161000.0 in 2023, then declined by 13.04% to $140000.0 in 2024, then slumped by 87.86% to $17000.0 in 2025, then decreased by 11.76% to $15000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $15000.0 (Q1 2026), $17000.0 (Q4 2025), and $19000.0 (Q3 2025), per Business Quant data.